Pfizer’s COVID vaccine has been widely applied to people. But you know what they say that there’s no such thing as perfection in this world. Mr. Albert Bourla, who is the CEO of Pfizer, brings a claim that will upset many people.
According to CNBC.com, Pfizer’s CEO says that the efficacy of the company’s COVID vaccine will decline steadily to roughly 84% at six months after a person gets the second dose.
Bourla’s comments were made during CNBC’s “The Exchange”. They’re based on the conclusions of a new study that has yet to be peer revived.
The peak was set at 96.2%
The same study concluded that Pfizer’s vaccine was most effective between one week and two months after a person receives the second dose. That maximum effectiveness was at 96.2%.
Bourla said, as quoted by CNBC.com:
We have seen also data from Israel that there is a waning of immunity and that starts impacting what used to be what was 100% against hospitalization. Now, after the six month period, is becoming low 90s and mid-to-high 80s.
The good news is that we are very, very confident that a third dose, a booster, will take up the immune response to levels that will be enough to protect against the delta variant.
Bourla also said that Pfizer aims to formally submit data to US regulators regarding the benefits of a third dose of COVID vaccine by the middle of August.
According to the CDC, clinical trials based on people of at least 16 years old showed that the vaccine developed by Pfizer-BioNTech was 95 percent effective for those who received two doses and weren’t previously infected with COVID.
The comment section is available for everyone to comment on. Feel free to share your thoughts with us.